---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-037018"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T19:35:10.771939+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protagonist Therapeutics CFO Don Kalkofen resigns effective April 1, 2022

## Summary
- CFO Don Kalkofen submitted resignation effective April 1, 2022.
- He will cease as principal financial and accounting officer upon resignation.
- Company has initiated a search for a replacement CFO.

## SEC filing metadata
- accession: 0001104659-22-037018
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465922037018/0001104659-22-037018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465922037018/tm2210222d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-037018
- JSON: https://secwatch.observer/filing/0001104659-22-037018.json
- Plain text: https://secwatch.observer/filing/0001104659-22-037018.txt

## Key facts
- Executive change
  Don Kalkofen departed as Chief Financial Officer at Protagonist Therapeutics, Inc.
  - Action: submitted notice of resignation
  - Role: Chief Financial Officer
  source text: On March 17, 2022, Don Kalkofen, the Chief Financial Officer of Protagonist Therapeutics, Inc. (the “Company”), submitted his notice of resignation from his position as Chief Financial Officer of the Company to be effective on April 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465922037018/0001104659-22-037018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.